Kidney Cancer Treatment

On This Page:

Kidney cancer, also called renal cell cancer, is one of the ten most common cancers in both men and women. Treatment options may include surgery (open or laparoscopic), local therapies such as ablation and embolization, active surveillance, radiation therapy, targeted therapy, immunotherapy, and chemotherapy. These treatments might be used alone or in combination, depending on various factors.

Surgery is the main treatment for most types of kidney cancer. Since 2000, the use of complete nephrectomy (removal of the whole kidney) in patients with localized kidney cancer or cancer in the immediate surrounding tissue (regional kidney cancer) has decreased, while the rate of partial nephrectomy (removal of only the affected part of the kidney) has increased. Although there are patients for whom it is not possible, partial nephrectomy is now the preferred treatment for patients with early stage kidney cancer,. Studies have shown long-term outcomes after partial nephrectomy and complete nephrectomy are about the same. Also, partial nephrectomy may prevent serious side effects like chronic kidney disease.

Systemic therapy (chemotherapy, targeted therapy, or immunotherapy) also may be used as a treatment for some individuals diagnosed with kidney cancer. Adjuvant systemic therapies such as pembrolizumab and sunitinib are sometimes used in the treatment of stage II and III kidney cancer, and a broader range of systemic options are used in metastatic disease.

Partial nephrectomy or complete nephrectomy in patients with localized/regional kidney cancer.

Receipt of systemic therapy among patients with kidney cancer.

Nephrectomy estimates: SEER 22 Registries, National Cancer Institute, 2004–2021.

Systemic therapy estimates: SEER Patterns of Care/Quality of Care Studies, National Cancer Institute, 2004-2019.

  • There are no Healthy People 2030 targets for cancer treatment, including kidney cancer treatment.

Healthy People 2030 is a set of goals set forth by the Department of Health and Human Services.

2004-2021
2017-2021
Non-Significant Change
Rising
Kidney, Lung, Ovarian, Prostate Treatment